(Q38099042)

28 August 2017

title

Pharmacological management of unipolar depression (English)

1 reference

28 August 2017

1 reference

3

1 reference

28 August 2017

G S Malhi

1

1 reference

28 August 2017

R Hitching

2

1 reference

28 August 2017

P Boyce

4

1 reference

28 August 2017

R Porter

5

1 reference

28 August 2017

K Fritz

6

1 reference

28 August 2017

publication date

1 January 2013

1 reference

Acta psychiatrica Scandinavica. Supplementum

28 August 2017

published in

1 reference

28 August 2017

issue

443

1 reference

28 August 2017

page(s)

6-23

1 reference

Clinical practice recommendations for depression

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Psychological management of unipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Lifestyle management of unipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

The Bech-Rafaelsen Melancholia Scale (MES) in clinical trials of therapies in depressive disorders: a 20-year review of its use as outcome measure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Measuring depressive symptoms in the naturalistic primary-care setting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Restoring melancholia in the classification of mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Continuity of antidepressant treatment for adults with depression in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR(*)D measurement-based care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

A systematic review of newer pharmacotherapies for depression in adults: evidence report summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

A systematic review of duloxetine and venlafaxine in major depression, including unpublished data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Clinically relevant pharmacology of neuropsychiatric drugs approved over the last three years: Part II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Impact of the novel antidepressant agomelatine on disturbed sleep-wake cycles in depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

The safety and tolerability of venlafaxine hydrochloride: analysis of the clinical trials database

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. IV. Neurostimulation therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Treatment strategies in patients with major depression not responding to first-line sertraline treatment. A randomised study of extended duration of treatment, dose increase or mianserin augmentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Dose escalation for insufficient response to standard-dose selective serotonin reuptake inhibitors in major depressive disorder: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Outcomes on the pharmacopsychometric triangle in bupropion-SR vs. buspirone augmentation of citalopram in the STAR*D trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Combining antidepressant medications: a good idea?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Dual-dual action? Combining venlafaxine and mirtazapine in the treatment of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Combination of antidepressants in the treatment of major depressive disorder: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

T3 augmentation in major depressive disorder: safety considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Augmentation of antidepressants with atypical antipsychotics: a review of the current literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Switching Antidepressants After a First Selective Serotonin Reuptake Inhibitor in Major Depressive Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Switching antidepressant class does not improve response or remission in treatment-resistant depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Efficacy of ECT in depression: a meta-analytic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Electroconvulsive therapy for depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Balancing speed of response to ECT in major depression and adverse cognitive effects: role of treatment schedule.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Evidence-based electroconvulsive therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Effect of concomitant pharmacotherapy on electroconvulsive therapy outcomes: short-term efficacy and adverse effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

ECT remission rates in psychotic versus nonpsychotic depressed patients: a report from CORE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Melancholic symptoms as assessed by the Hamilton Depression Rating Scale and outcomes with and without electroconvulsive therapy on an in-patient mood disorders unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Repetitive transcranial magnetic stimulation in combination with citalopram in young patients with first-episode major depressive disorder: a double-blind, randomized, sham-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Subcallosal cingulate gyrus deep brain stimulation for treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Deep brain stimulation for treatment-resistant depression: follow-up after 3 to 6 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Deep brain stimulation in the treatment of depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Genome-wide association study of major recurrent depression in the U.K. population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Genome-wide pharmacogenetics of antidepressant response in the GENDEP project

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Variation in brain-derived neurotrophic factor (BDNF) gene is associated with symptoms of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

The role of BDNF and its receptors in depression and antidepressant drug action: Reactivation of developmental plasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Genetic association study of BDNF in depression: finding from two cohort studies and a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Serotonin transporter gene moderates childhood maltreatment's effects on persistent but not single-episode depression: replications and implications for resolving inconsistent results

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Personality disorder and the outcome of depression: meta-analysis of published studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Subthreshold hypomanic symptoms in progression from unipolar major depression to bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Major depressive disorder with subthreshold bipolarity in the National Comorbidity Survey Replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Diagnostic conversion from depression to bipolar disorders: results of a long-term prospective study of hospital admissions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Mood episodes and mood disorders: patterns of incidence and conversion in the first three decades of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Bipolar disorder at prospective follow-up of adults who had prepubertal major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Meta-analysis of major depressive disorder relapse and recurrence with second-generation antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

A 5-year prospective study of predictors for disability pension among patients with major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Discontinuing antidepressant treatment in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Relapse after recovery from unipolar depression: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Effectiveness of interventions to improve antidepressant medication adherence: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

The association between antidepressant dosage titration and medication adherence among patients with depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Therapeutic rationale of antidepressant use in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Slow versus standard up-titration of paroxetine for the treatment of depression in cancer patients: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

A multifactorial developmental model for the etiology of major depression in a population-based sample.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

The relationship between social support and major depression: cross-sectional, longitudinal, and genetic perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

A comparative clinical trial of fluoxetine, mianserin and placebo in depressed outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Fluoxetine versus moclobemide: cross-comparison between the time courses of improvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

Early discontinuation of antidepressants in general practice: association with patient and prescriber characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FACPS.12122

21 January 2018

Identifiers

DOI

10.1111/ACPS.12122

1 reference

28 August 2017

1 reference